Clinical Trial

Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 10, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults. The main question it aims to answer is: • Does DHA increase terminal hair follicles in the vertex area. Researchers will compare oral DHA plus topical minoxidil to topical minoxidil alone in female patients with AGA to see if DHA works to alleviate AGA. Participants will: * Receive oral DHA every day plus topical minoxidil or use topical minoxidil alone for 6 months. * Visit the clinic once every month for checkups and tests.
Trial Details
NCT Number NCT07012486
Lead Sponsor Shanghai Zhongshan Hospital
Conditions Androgenetic Alopecia (AGA)
Enrollment 30 participants
Start Date 2025-06
Primary Completion 2026-05 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-06-10